News

SAGA Diagnostics enters into Development Agreement with AstraZeneca

  LUND, Sweden — /November 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN).   SAGA Diagnostics will…

SAGA hires two new scientists to strengthen its R&D Team

LUND, Sweden — /October 28, 2021/ — SAGA Diagnostics AB, (“SAGA”), a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces that it has hired two new scientists to significantly strengthen SAGA’s Research and Development Team: Nuria Seguí, PhD as…

Proof of concept SAGAsafe® 24-plex ultrasensitive compatibility demonstrated on naica® Prism 6 dPCR instrument

LUND, Sweden — /October 20, 2021/ — SAGA Diagnostics AB, “SAGA”, a leading cancer liquid biopsy and genomic testing company, adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society…

SAGA Diagnostics appoints Peter Collins as Chief Executive Officer

LUND, Sweden — /October 7, 2021/ — SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer.   Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics…

Now recruiting: Bioinformatics Scientist

Bioinformatics Scientist   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive…

SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies

  LUND, Sweden, and STOCKHOLM, Sweden — /June 29, 2021/ — SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led…

SAGA expands research collaboration with University College London Cancer Institute

  LUND, Sweden — /June 17, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute.   Last…

SAGA Diagnostics achieves ISO 17025 accreditation by SWEDAC for mutation testing services

  LUND, Sweden — /June 15, 2021/ — SAGA Diagnostics AB (“SAGA”), today announced that it has successfully been accredited to the ISO 17025 standard for its leading-edge mutation detection laboratory services designed to radically improve cancer diagnosis, monitoring, and treatment outcomes.  Granted by SWEDAC, the Swedish Board for Accreditation…

Now recruiting: Molecular Diagnostics Scientist Digital PCR

Molecular Diagnostics Scientist, Digital PCR   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated digital PCR (dPCR) scientist with strong interest in advancing our mission to revolutionize…

SAGAsafe® technology utilized in new study of ESR1 mutations in breast cancer

  LUND, Sweden — /April 22, 2021/ — ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied…